Reimers, M. A., Iyer, G., Powles, T., Drakaki, A., Siefker-Radtke, A. O., Loriot, Y., Matsubara, N., Eigl, B. J., Robbrecht, D. G., Jain, R. K., Zhao, X., Szymczak, S., Sherwood, S., Schaverien, C., Gao, X. (2026). FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps895